{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-006614","form_type":"8-K/A","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.137191+00:00","generated_at":"2026-06-07T00:31:13.261014+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aileron provides Lung Therapeutics financials: net loss $19M in 2022, accumulated deficit $63M, going concern cited","bullets":["Lung Therapeutics net loss $19.0M in 2022, $9.9M in 2021; cash and equivalents $11.9M at Dec 31, 2022.","Accumulated deficit $63.4M; auditor's report includes substantial doubt about going concern.","Lung's lead candidate LTI-03 (IPF) in Phase 1b; LTI-01 (LPE) completed Phase 2.","Pro forma condensed combined financial statements also filed with this 8-K/A."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-006614","json":"https://secwatch.observer/filing/0001193125-24-006614.json","markdown":"https://secwatch.observer/filing/0001193125-24-006614.md","text":"https://secwatch.observer/filing/0001193125-24-006614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524006614/0001193125-24-006614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524006614/d22567d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:31:13.261014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}